Clearside Biomedical Inc (NASDAQ:CLSD) is a company that focuses in the development of working pharmacological therapies. The therapies by this business guru help in dealing with the blinding diseases of the eye and other vision defects. This business has its headquarters in Alpharetta, Georgia. The results of the Phase 3 clinical trial are already out. However, the study failed to meet its primary end point.
Current state of affairs
Clearside Biomedical seeks to find solutions that help handle retinal vein occlusion (‘RVO”).Its latest study sought to establish the effectiveness of XIPERE in combination with intravitreal Eylea monotherapy.
The study took into account a group of patients under the combination treatment arm. Reports indicate that the study used these as the trial’s primary endpoint. This study struck a comparison between this and the proportion under the intravitreal Eylea-alone control arm. This study also targeted establishing what worked in line with correcting visual acuity.
A closer outlook
The SAPPHIRE trial involved two arms and the company has a lot to learn from the results. They indicate that almost 50% of patients in each of the arms showcased remarkable improvements. Each patient witnessed a 15 letter enhancement in vision.
The patients treated with XIPERE in close combination with intravitreal Eylea didn’t receive the expected additional benefits. That has become a major cause for concern in line with the recent study.
The President of Clearside Daniel White opined, “In light of these 8-week topline data, we plan to discontinue clinical development of combination therapy for RVO, which includes SAPPHIRE and its companion Phase 3 clinical trial, TOPAZ.”
Mr. White says that uveitis serves them with a remarkable opportunity. This of course happens to be the company’s primary indication. The official also speaks in relation to the increased acceptance and awareness in line with XIPERE.
The strong clinical profile of the substance moves the company a notch higher in the list of innovative companies.
It seeks to work on the product to ensure its effectiveness in handling uveitic macular edema. The company outlines that before the end of this particular year it will have submitted its NDA.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.